BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30304046)

  • 1. Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
    Schernberg A; Mezquita L; Boros A; Botticella A; Caramella C; Besse B; Escande A; Planchard D; Le Péchoux C; Deutsch E
    PLoS One; 2018; 13(10):e0204490. PubMed ID: 30304046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation.
    Schernberg A; Moureau-Zabotto L; Rivin Del Campo E; Escande A; Ducreux M; Nguyen F; Goere D; Chargari C; Deutsch E
    Oncotarget; 2017 Feb; 8(7):11579-11588. PubMed ID: 28086222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation.
    Schernberg A; Huguet F; Moureau-Zabotto L; Chargari C; Rivin Del Campo E; Schlienger M; Escande A; Touboul E; Deutsch E
    Radiother Oncol; 2017 Jul; 124(1):110-117. PubMed ID: 28662871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocytosis and neutrophilia predicts outcome in anal cancer.
    Schernberg A; Escande A; Rivin Del Campo E; Ducreux M; Nguyen F; Goere D; Chargari C; Deutsch E
    Radiother Oncol; 2017 Jan; 122(1):137-145. PubMed ID: 28024835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophilia in locally advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy?
    Escande A; Haie-Meder C; Maroun P; Gouy S; Mazeron R; Leroy T; Bentivegna E; Morice P; Deutsch E; Chargari C
    Oncotarget; 2016 Nov; 7(46):74886-74894. PubMed ID: 27713124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy.
    Schernberg A; Blanchard P; Chargari C; Ou D; Levy A; Gorphe P; Breuskin I; Atallah S; Caula A; Escande A; Janot F; Nguyen F; Temam S; Deutsch E; Tao Y
    Clin Transl Radiat Oncol; 2018 Aug; 12():8-15. PubMed ID: 30073209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
    Hoffmann M; Reitz D; Taugner J; Roengvoraphoj O; Käsmann L; Eze C; Karin M; Belka C; Manapov F
    Anticancer Res; 2020 Apr; 40(4):2319-2322. PubMed ID: 32234932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort.
    Sun H; Hu P; Shen H; Dong W; Zhang T; Liu Q; Du J
    PLoS One; 2015; 10(12):e0144663. PubMed ID: 26656866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Mo D; He F
    Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.